Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial

Graphical abstract

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2019-10, Vol.97, p.82-91
Hauptverfasser: Haddad, Robert, Guigay, Joel, Keilholz, Ulrich, Clement, Paul M, Fayette, Jérôme, de Souza Viana, Luciano, Rolland, Frédéric, Cupissol, Didier, Geoffrois, Lionnel, Kornek, Gabriela, Licitra, Lisa, Melichar, Bohuslav, Ribaldo Nicolau, Ulisses, Rauch, Daniel, Zanetta-Devauges, Sylvie, Cohen, Ezra E.W, Machiels, Jean-Pascal, Tahara, Makoto, Vermorken, Jan, Geng, Yuan, Zografos, Eleftherios, Gauler, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Adherence
Afatinib
Feeding tube
Hematology, Oncology, and Palliative Medicine
HNSCC
Methotrexate
Otolaryngology
Recurrent/metastatic
Safety
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Graphical abstract
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2019.08.004